Innovative Pricing and Payment Models for Health Technologies

By João L. Carapinha

October 22, 2024

pricing payment schemes

The article titled “Design and Features of Pricing and Payment Schemes for Health Technologies,” centers on the crucial topic of pricing and payment (P&P) schemes for health technologies in the healthcare sector. The discussion encompasses key aspects that influence this domain, providing insights on how these schemes can effectively address current challenges.

Objective

The article aims to map existing types of pricing and payment schemes for health technologies while proposing a new, flexible, need-driven classification system that enhances understanding and applicability.

Context

Given the increasing clinical and financial uncertainty in the healthcare sector, innovative pricing and payment schemes are being explored as potential solutions to these persistent challenges.

Current Schemes

The article conducts a scoping review to identify and categorize the various P&P schemes currently in use for health technologies. This includes different models such as:

  • Fixed pricing
  • Value-based pricing
  • Risk-sharing agreements
  • Pay-for-performance models
  • Subscription-based models

Proposed Classification

The authors propose a new classification system that is both flexible and need-driven. This system is designed to help policymakers, healthcare providers, and manufacturers navigate the complex landscape of P&P schemes more effectively. It considers various factors, including the type of health technology and the specific needs of different healthcare systems.

Key Features

The article highlights several key features of effective pricing and payment schemes, which include:

  • Flexibility: The ability to adapt to evolving healthcare needs and financial constraints.
  • Value-Based: Schemes that tie payments to actual health outcomes or to the value delivered by the health technology.
  • Risk Management: Mechanisms that distribute risk among manufacturers, payers, and providers.
  • Innovation Incentives: Schemes designed to encourage the development and adoption of new health technologies.

Implications

The proposed classification and analysis of P&P schemes have significant implications for healthcare policy, practice, and research. It can aid in:

  • Improving the sustainability of healthcare systems
  • Enhancing access to innovative health technologies
  • Aligning payments with health outcomes
  • Reducing financial uncertainty for various stakeholders involved.

In summary, the article provides a comprehensive framework for understanding and improving the design and implementation of P&P schemes in the healthcare sector, ultimately serving as a vital tool in addressing current challenges. The focus on pricing and payment schemes is essential for fostering effective health technology utilization and ensuring ongoing innovation.

Reference url

Recent Posts

medtech market access strategy
Prioritizing a Comprehensive Medtech Market Access Strategy Through Stakeholder Engagement

By João L. Carapinha

June 9, 2026

An effective medtech market access strategy must begin at the concept stage by simultaneously addressing patient needs, clinical workflows, regulatory requirements, and payer expectations rather than defaulting to FDA clearance as the sole priority. Startups that ignore this broader view risk bui...
HIV Weekly Treatment Options
Potential for Advancements in HIV Weekly Treatment Options

By João L. Carapinha

June 9, 2026

HIV Weekly Treatment Options took a major step forward as Gilead and Merck reported that their investigational once-weekly combination of islatravir and lenacapavir successfully met the primary endpoint in two Phase 3 trials. The oral regimen maintained viral suppression in adults already control...
Tovorafenib clinical assessment
Tovorafenib Clinical Assessment Outcomes and Methodological Challenges

By João L. Carapinha

June 9, 2026

The Tovorafenib clinical assessment conducted under the EU Joint Clinical Assessment process has exposed critical shortcomings in the evidence base for treating BRAF-altered pediatric low-grade glioma. Despite the therapy’s potential, reviewers concluded that robust comparative data is absent for...